MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s43018-024-00810-4

Медицинская библиотека · Nature cancer · 2024

A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma.

Dimitriou Florentia, Cheng Phil F, Saltari Annalisa, Schaper-Gerhardt Katrin, Staeger Ramon, Haunerdinger Veronika, Sella Federica, Tastanova Aizhan, Urban Christian, Dettwiler Susanne, Mihic-Probst Daniela, Matter Christian M, Michielin Olivier, Gutzmer Ralf, Long Georgina V, Becher Burkhard, Levesque Mitchell P, Dummer Reinhard

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Immune checkpoint inhibitors are standard-of-care for the treatment of advanced melanoma, but their use is limited by immune-related adverse events. Proteomic analyses and multiplex cytokine and chemokine assays from serum at baseline and at the adverse event onset indicated aberrant T cell activity with differential expression of type I and III immune signatures. This was in line with the finding of an increase in the proportion of CD4+ T cells with IL-17A expression at the adverse event onset in the peripheral blood using flow cytometry. Multiplex immunohistochemistry and spatial transcriptomics on immunotherapy-induced skin rash and colitis showed an increase in the proportion of CD4+ T cells with IL-17A expression. Anti-IL-17A was administered in two patients with mild myocarditis, colitis and skin rash with resolution of the adverse events. This study highlights the potential role of type III CD4+ T cells in adverse event development and provides proof-of-principle evidence for a clinical trial using anti-IL-17A for treating adverse events.

Для цитирования: Dimitriou Florentia, Cheng Phil F, Saltari Annalisa, Schaper-Gerhardt Katrin, Staeger Ramon, Haunerdinger Veronika, Sella Federica, Tastanova Aizhan, Urban Christian, Dettwiler Susanne, Mihic-Probst Daniela, Matter Christian M, Michielin Olivier, Gutzmer Ralf, Long Georgina V, Becher Burkhard, Levesque Mitchell P, Dummer Reinhard. A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma.. Nature cancer. 2024. DOI: 10.1038/s43018-024-00810-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.